Envoy Medical (COCH) Expected to Release Earnings on Thursday

Envoy Medical (NASDAQ:COCH) is expected to release its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.70) per share and revenue of $0.09 million for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 9:30 AM ET.

Envoy Medical (NASDAQ:COCH) last posted its earnings results on Monday, August 10th. The company reported ($0.70) EPS for the quarter, beating the consensus estimate of ($0.80) by $0.10. The business had revenue of $0.05 million during the quarter, compared to analysts’ expectations of $0.05 million. On average, analysts expect Envoy Medical to post ($3.10) EPS for the current fiscal year and ($1.80) EPS for the next fiscal year.

Envoy Medical Stock Up 5.0%

Envoy Medical stock traded up $0.33 during midday trading on Tuesday, reaching $6.98. The company’s stock had a trading volume of 4,207 shares, compared to its average volume of 39,102. The company has a market cap of $53.89 million, a P/E ratio of -0.92 and a beta of 1.97. The business has a 50-day simple moving average of $6.85 and a 200-day simple moving average of $6.87. Envoy Medical has a fifty-two week low of $3.63 and a fifty-two week high of $9.54.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on COCH. Weiss Ratings reissued a “sell (e+)” rating on shares of Envoy Medical in a research report on Monday, October 19th. Lake Street Capital upped their price target on Envoy Medical from $2.50 to $25.00 and gave the company a “buy” rating in a report on Tuesday, October 27th. HC Wainwright reiterated a “buy” rating on shares of Envoy Medical in a research note on Tuesday, October 13th. Finally, Loop Capital set a $20.00 price objective on shares of Envoy Medical in a report on Monday, July 27th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $21.67.

About Envoy Medical

Envoy Medical is a medical technology company focused on developing fully implanted hearing devices for people with sensorineural hearing loss. Unlike conventional hearing aids and many cochlear implants, its technology is designed to be placed beneath the skin, with no external wearable sound processor.

The company’s lead product is the Acclaim Cochlear Implant, a fully implanted cochlear implant intended to address moderate-to-profound sensorineural hearing loss in adults. The system is designed to use the body’s natural anatomy to capture sound and convert it into electrical signals that stimulate the auditory nerve.